MRK logo

MRK
Merck & Co Inc

25,729
Mkt Cap
$286.2B
Volume
6.98M
52W High
$125.14
52W Low
$75.40
PE Ratio
32.61
MRK Fundamentals
Price
$121.86
Prev Close
$115.88
Open
$121.10
50D MA
$115.57
Beta
0.32
Avg. Volume
9.33M
EPS (Annual)
$7.28
P/B
6.24
Rev/Employee
$865,680.00
$299,786.82
Loading...
Loading...
News
all
press releases
Merck Stock Gains On Positive EU Opinion For Cancer Therapy
Merck’s KEYTRUDA + Padcev Bladder Cancer Combination Edges Closer To EU Approval.
News Placeholder
More News
News Placeholder
Here's Why You Should Add SMMT Stock to Your Portfolio Now
Summit Therapeutics advances ivonescimab with late-stage NSCLC and CRC studies, with FDA review underway and new partnerships expanding its oncology reach.
News Placeholder
Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in combination with...
News Placeholder
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?
Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.
News Placeholder
Eli Lilly vs. Merck: Which Pharma Stock Looks Stronger Now?
LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.
News Placeholder
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
News Placeholder
Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion
PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.
News Placeholder
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.
News Placeholder
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
News Placeholder
Merck's ADC Candidate Meets Goals in Endometrial Cancer Study
MRK's investigational TROP2-directed ADC, sac-TMT, achieves key survival goals in a phase III endometrial cancer study.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available